Preparing to use denosumab 60mg biosimilar(161 KB)
Date added: 16th Mar 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Green | Management of overweight and obesity |
For managing overweight and obesity in adults in line with NICE TA1026. March 2026: Green for eligible cohort only as per LLR weight management guide or access via LLR specialist weight loss clinic |
| DENOSUMAB (Jubereq®) (NEW) | Orange | Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate |
Biosimilar of denosumab; preferred first-line option in LLR for prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate (120mg vial). Preparing to use denosumab 120mg biosimilar |
| DENOSUMAB (Ponlimisi®) (NEW) | Orange | Osteoporosis |
Biosimilar of denosumab; preferred first-line option in LLR for osteoporosis (60mg PFS). Preparing to use denosumab 60mg biosimilar
|
| HYDRALAZINE (UPDATED) | Yellow | Hypertension & Heart Failure | |
| Inbrija | Yellow | Indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor (1) | |
| OMEPRAZOLE DISPERSIBLE (UPDATED) | Green |
2nd line choice dispersible PPI |
Other Updates on this Website
Recent documents from LLR APC and TAS
Preparing to use denosumab 120mg biosimilar(163 KB)
Date added: 16th Mar 2026
LLRAPC Newsletter – February 2026(780 KB) - LMSG/LLR APC newsletters
Date added: 11th Mar 2026
LLR APC Minutes 2025(3 MB) - LMSG/LLR APC minutes
Date added: 9th Mar 2026
LLR APC Meeting Minutes – February 2026(423 KB) - LMSG/LLR APC minutes
Date added: 9th Mar 2026
Leflunomide Rheumatology Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Mycophenolate Rheumatology Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Mycophenolate Dermatology Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Mycophenolate Neurology Shared Care Request Form National Format(68 KB)
Date added: 5th Mar 2026
Mycophenolate Respiratory Shared Care Request Form National Format(69 KB)
Date added: 5th Mar 2026
Methotrexate Rheumatology Request Form(70 KB)
Date added: 5th Mar 2026
Methotrexate Adult Gastroenterology Request Form(69 KB)
Date added: 5th Mar 2026
Methotrexate dermatology request form(163 KB)
Date added: 5th Mar 2026
LLR APC Newsletter December 2025 / January 2026(582 KB) - LMSG/LLR APC newsletters
Date added: 19th Feb 2026
Methotrexate Rheumatology/Dermatology/Gastroenterology SCA(523 KB) - Shared care agreement
Date added: 29th Dec 2022
Continence Prescribing Formulary for LLR(624 KB) - Guidelines
Date added: 9th Aug 2018
Leflunomide Shared Care Agreement(465 KB) - Shared care agreement
Date added: 4th May 2016
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more